Targeted Medical Pharma (OTCMKTS:TRGM) and Supernus Pharmaceuticals (NASDAQ:SUPN) Financial Review

Targeted Medical Pharma (OTCMKTS:TRGM) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, earnings, analyst recommendations, risk and valuation.

Valuation and Earnings

This table compares Targeted Medical Pharma and Supernus Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Targeted Medical Pharma	N/A	N/A	N/A	N/A	N/A
Supernus Pharmaceuticals	$681.54 million	3.81	$73.86 million	($0.34)	-133.29

Supernus Pharmaceuticals has higher revenue and earnings than Targeted Medical Pharma.

Profitability

This table compares Targeted Medical Pharma and Supernus Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Targeted Medical Pharma	N/A	N/A	N/A
Supernus Pharmaceuticals	9.70%	14.22%	10.82%

Analyst Recommendations

This is a summary of current recommendations and price targets for Targeted Medical Pharma and Supernus Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Targeted Medical Pharma	0	0	0	0	0.00
Supernus Pharmaceuticals	1	0	4	1	2.83

Supernus Pharmaceuticals has a consensus target price of $63.25, suggesting a potential upside of 39.56%. Given Supernus Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Supernus Pharmaceuticals is more favorable than Targeted Medical Pharma.

Summary

Supernus Pharmaceuticals beats Targeted Medical Pharma on 8 of the 8 factors compared between the two stocks.

About Targeted Medical Pharma

Targeted Medical Pharma, Inc., a specialty pharmaceutical company, doing business as Physician Therapeutics, develops and commercializes amino acid based medications to physicians, pharmacies, and patients in the United States. It offers a line of patented amino acid based medical food products, dietary supplements, and generic drugs primarily for the treatment of metabolic syndrome/obesity; sleep disorders associated with anxiety; hypertension; viral infections; cognitive disorders/fatigue; sleep disorders associated with depression, fibromyalgia, and PTSD; pain disorders and inflammatory conditions/fibromyalgia; osteoarthritis and joint disorders; and peripheral neuropathy. The company also provides a proprietary billing process and supporting software (PDRx) that facilitates physician dispensing; provides inventory control; and assists regulatory reporting. In addition, it offers billing and collection services relating to its products on behalf of dispensing physician clients to private insurance and workers' compensation insurance. Targeted Medical Pharma, Inc. distributes its products through a network of distributors and an internal sales force that sells products directly to dispensing physician clients. The company was formerly known as Targeted Medical Foods and changed its name to Targeted Medical Pharma, Inc. in 2006. Targeted Medical Pharma, Inc. was founded in 1996 and is headquartered in Los Angeles, California.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.